Structure Therapeutics Inc. – NASDAQ:GPCR

Add to watchlist

$18.92

-10.11

-34.85%

Market closed

Open in about 3 hours

-33.82%

month

-33.82%

quarter

-20.00%

year

Market Cap	1.59B
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-2.32

Revenue	N/A
EBITDA	-114.99M
Income	-97.84M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Structure Therapeutics Inc. (NASDAQ:GPCR): Profit margin
Jun 2023	0	-23.28M
Sep 2023	0	-23.86M
Dec 2023	1.32M	-24.67M	-1855.04%
Mar 2024	0	-26.03M

Structure Therapeutics Financials Estimate

Q Y

Structure Therapeutics Inc. (NASDAQ:GPCR): Analyst Estimates
Mar 2024	0	-26.03M
Sep 2025	0	-13.45M
Oct 2025	0	-13.97M
Dec 2025	0	-15.21M

Analysts Price target
Financials & Ratios estimates

Structure Therapeutics Inc. (NASDAQ:GPCR): Earnings per share (EPS)
2023-11-14	-0.29	-0.62
2024-03-08	-0.21	-0.17
2024-05-09	-0.21	-0.19

Structure Therapeutics Inc. (NASDAQ:GPCR): Debt to assets
Jun 2023	229428000	15.01M	6.54%
Sep 2023	216370000	23.40M	10.82%
Dec 2023	482017096	29.05M	6.03%
Mar 2024	457220419	27.40M	5.99%

Structure Therapeutics Inc. (NASDAQ:GPCR): Cash Flow
Jun 2023	-16.89M	-68.71M	-297K
Sep 2023	-20.55M	30.12M	473K
Dec 2023	-21.90M	-180.88M	281.97M
Mar 2024	-34.02M	1.41M	700.85K

Structure Therapeutics alternative data

Structure Therapeutics
Employees

Structure Therapeutics Inc. (NASDAQ:GPCR): Employee count
Aug 2023	68
Sep 2023	77
Oct 2023	77
Nov 2023	77
Dec 2023	87
Jan 2024	87
Feb 2024	87
Mar 2024	93
Apr 2024	93
May 2024	93
Jun 2024	93
Jul 2024	111

Structure Therapeutics
Hedge Funds Holdings Q1 2023

42.65% +42.65%

of GPCR is owned by hedge funds

13 +13

hedge funds hold GPCR stock

3.86M +3.86M

shares is hold by hedge funds

GPCR hedge funds holdings changes

Structure Therapeutics
Insider Trading

Structure Therapeutics Inc. (NASDAQ:GPCR): Insider trades (number of shares)
Period	Buy	Sel
Oct 2023	0	17454
Dec 2023	0	17454
Feb 2024	0	525
Mar 2024	0	21997
Jun 2024	0	220400

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	10 Jun 2024	STEVENS RAYMOND C director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	American Depositary Shares	185,000	N/A	N/A
Sale	3 Jun 2024	LIN XICHEN officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	American Depositary Shares	17,700	N/A	N/A
Sale	3 Jun 2024	LIN XICHEN officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	American Depositary Shares	17,700	N/A	N/A
Option	3 Jun 2024	LIN XICHEN officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	Share Option (right to buy)	106,200	$0.34	$36,108
Option	3 Jun 2024	LIN XICHEN officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	Ordinary Shares	106,200	$0.34	$36,108
Sale	14 Mar 2024	FMR LLC 10 percent owner, other: See Remark 1 10 percent owner, other: See Re..	American Depositary Shares	21,997	N/A	N/A
Sale	13 Feb 2024	FMR LLC 10 percent owner, other: See Remark 1 10 percent owner, other: See Re..	American Depositary Shares	525	N/A	N/A
Sale	5 Dec 2023	FMR LLC 10 percent owner 10 percent owner	American Depositary Shares	16,086	N/A	N/A
Sale	5 Dec 2023	FMR LLC 10 percent owner 10 percent owner	American Depositary Shares	1,368	N/A	N/A
Sale	18 Oct 2023	FMR LLC 10 percent owner 10 percent owner	American Depositary Shares	16,086	N/A	N/A

GPCR insider trading transactions

Structure Therapeutics
Latest News

Tuesday, 17 December 2024
16:01	Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity	globenewswire.com
Thursday, 5 December 2024
18:17	Structure CEO on the competitive landscape for oral GLP-1 drugs	youtube.com
Tuesday, 19 November 2024
14:10	Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones	benzinga.com
Friday, 15 November 2024
08:30	Structure Therapeutics to Participate in the Jefferies London Healthcare Conference	globenewswire.com
Wednesday, 13 November 2024
16:01	Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity	globenewswire.com
Tuesday, 5 November 2024
02:00	Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI	globenewswire.com
Wednesday, 23 October 2024
11:15	Best Momentum Stocks to Buy for October 23rd	zacks.com
Tuesday, 22 October 2024
14:07	Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients	seekingalpha.com
Wednesday, 9 October 2024
10:56	Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?	zacks.com
Tuesday, 17 September 2024
16:05	Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.	globenewswire.com
Thursday, 12 September 2024
11:50	Five Top Obesity Stocks to Buy and Hold Long Term	247wallst.com
Tuesday, 27 August 2024
16:05	Structure Therapeutics Appoints Angus C. Russell to Board of Directors	globenewswire.com
Monday, 26 August 2024
16:05	Structure Therapeutics Announces Participation in Upcoming Investor Conferences	globenewswire.com
12:00	Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say	marketwatch.com
Tuesday, 13 August 2024
14:00	3 Promising Biotech Stocks for the Long-Term: August 2024	investorplace.com
Wednesday, 24 July 2024
09:56	What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?	zacks.com
Monday, 22 July 2024
09:20	Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.	fool.com
Friday, 12 July 2024
06:08	The 3 Most Undervalued Biotech Stocks to Buy in July 2024	investorplace.com
Friday, 28 June 2024
10:09	The 3 Smartest Biotech Stocks to Buy With $5K Right Now	investorplace.com
Monday, 17 June 2024
09:53	Could Structure Therapeutics Become the Next Novo Nordisk?	fool.com
Tuesday, 11 June 2024
18:37	Structure Therapeutics CEO on GLP drugs	youtube.com
11:00	Structure Therapeutics (GPCR) Rallying on Obesity Drug Data	zacks.com
04:57	Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?	fool.com
Sunday, 9 June 2024
07:30	Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?	fool.com
Friday, 7 June 2024
16:05	Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares	globenewswire.com
Wednesday, 5 June 2024
19:53	Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering	globenewswire.com
Tuesday, 4 June 2024
06:00	The 3 Most Undervalued Biotech Stocks to Buy in June 2024	investorplace.com
Monday, 3 June 2024
18:27	Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz	youtube.com
16:09	Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants	globenewswire.com
15:30	Structure Therapeutics (GPCR) Stock Soars 60% on Weight Loss Drug Success	investorplace.com

Ideas & Opinions

Seeking Alpha 16 May 2025

Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound
Seeking Alpha 19 Dec 2024

Viking Therapeutics: Competition Fears Are Exaggerated
Seeking Alpha 13 Jun 2024

Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon
Seeking Alpha 4 Oct 2023

Structure Therapeutics: Tipping The Scales In Obesity Management
Seeking Alpha 29 Jul 2023

U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs
Seeking Alpha 12 Apr 2023

Structure Therapeutics: Developing Innovative Treatments For Metabolic And Fibrotic Diseases

Frequently Asked Questions (FAQ)

What's the price of Structure Therapeutics stock today?

One share of Structure Therapeutics stock can currently be purchased for approximately $18.92.
When is Structure Therapeutics's next earnings date?

Unfortunately, Structure Therapeutics's (GPCR) next earnings date is currently unknown.
Does Structure Therapeutics pay dividends?

No, Structure Therapeutics does not pay dividends.
How much money does Structure Therapeutics make?

Structure Therapeutics has a market capitalization of 1.59B. Structure Therapeutics made a loss 89.62M US dollars in net income (profit) last year or -$0.19 on an earnings per share basis.
What is Structure Therapeutics's stock symbol?

Structure Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "GPCR".
What is Structure Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Structure Therapeutics?

Shares of Structure Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Structure Therapeutics have?

As Jul 2024, Structure Therapeutics employs 111 workers, which is 19% more then previous month and 19% more then previous quarter.
When Structure Therapeutics went public?

Structure Therapeutics Inc. is publicly traded company for more then 2 years since IPO on 3 Feb 2023.
What is Structure Therapeutics's official website?

The official website for Structure Therapeutics is structuretx.com.
Where are Structure Therapeutics's headquarters?

Structure Therapeutics is headquartered at 611 Gateway Boulevard, South San Francisco, CA.
How can i contact Structure Therapeutics?

Structure Therapeutics's mailing address is 611 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +62 82299277.

Structure Therapeutics Inc.

structuretx.com

Exchange:

NASDAQ

Full time employees:

136

Industry:

Biotechnology

Sector:

Healthcare

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

+62 82299277

611 Gateway Boulevard
South San Francisco, CA 94080

CIK: 0001888886
ISIN: US86366E1064
CUSIP: 86366E106